{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:39Z","timestamp":1789430439541,"version":"build-2803163510"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T00:00:00Z","timestamp":1386806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0083374","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T01:12:38Z","timestamp":1386897158000},"page":"e83374","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":51,"title":["Next Generation Inactivated Polio Vaccine Manufacturing to Support Post Polio-Eradication Biosafety Goals"],"prefix":"10.1371","volume":"8","author":[{"given":"Yvonne E.","family":"Thomassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart G.","family":"van \u2019t Oever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique G. C. T.","family":"van Oijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 H.","family":"Wijffels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo A.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried A. M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,12,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0264-410X(98)90035-4","article-title":"Vaccinology of poliomyelitis","volume":"2","author":"D Salk","year":"1984","journal-title":"Vaccine"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2011.10.005","article-title":"The global polio eradication initiative: Lessons learned and prospects for success","volume":"29","author":"B Aylward","year":"2011","journal-title":"Vaccine"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated Polio Vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"WAM Bakker","year":"2011","journal-title":"Vaccine"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0092-1157(73)90048-6","article-title":"History of Sabin attenuated poliovirus oral live vaccine strains","volume":"1","author":"AB Sabin","year":"1973","journal-title":"J Biol Stand"},{"key":"ref5","year":"2002"},{"key":"ref6","article-title":"WHO global action plan to minimize poliovirus facility-associated risk after eradication of wild polioviruses and cessation of routine OPV use (Draft 2009)","year":"2009"},{"key":"ref7","year":"2004"},{"key":"ref8","article-title":"Global post-eradication IPV supply and demand assessment: integrated findings commisioned by the Bill & Melinda Gates Foundation and prepared by Oliver Wyman Inc. Available","author":"L Venczel","year":"2009"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"OM Kew","year":"2005","journal-title":"Annu Rev Microbiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/216064a0","article-title":"Growth of cell-strains and primary cells on micro-carriers in homogeneous culture","volume":"216","author":"AL van Wezel","year":"1967","journal-title":"Nature"},{"key":"ref11","first-page":"65","article-title":"Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines","volume":"42","author":"AL van Wezel","year":"1979","journal-title":"Dev Biol Stand"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/bit.22788","article-title":"Multivariate data analysis on historical IPV production data for better process understanding and future improvements","volume":"107","author":"YE Thomassen","year":"2010","journal-title":"Biotechnol Bioeng"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/bit.24798","article-title":"Scale-down of the inactivated polio vaccine production process","volume":"110","author":"YE Thomassen","year":"2013","journal-title":"Biotechnol Bioeng"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0264-410X(98)00409-5","article-title":"Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains","volume":"17","author":"G Kersten","year":"1999","journal-title":"Vaccine"},{"key":"ref15","article-title":"Lessons learned in the transfer of Hib conjugate vaccine technology and the consequences for access to this vaccine in developing countries","author":"H Kreeftenberg","year":"2007"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biologicals.2006.02.011","article-title":"Technology transfer of Sabin-IPV to new developing country markets","volume":"34","author":"H Kreeftenberg","year":"2006","journal-title":"Biologicals"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/0264-410X(92)90323-C","article-title":"The Children's Vaccine Initiative and vaccine supply: the role of the public sector","volume":"10","author":"RB van Noort","year":"1992","journal-title":"Vaccine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/vim.1990.3.243","article-title":"Production of poliovirus vaccines: past, present, and future","volume":"3","author":"M Duchene","year":"1990","journal-title":"Viral Immunol"},{"key":"ref19","article-title":"Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults","author":"P Verdijk","year":"2012"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.vaccine.2013.09.021","article-title":"Safety and Immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults","volume":"31","author":"P Verdijk","year":"2013","journal-title":"Vaccine"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.procbio.2011.11.006","article-title":"Transfer of an adherent Vero cell culture method between two different rocking motion type bioreactors with respect to cell growth and metabolic rates","volume":"47","author":"YE Thomassen","year":"2012","journal-title":"Process Biochem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biologicals.2011.11.004","article-title":"Development of a fast ELISA for quantifying polio D-antigen in in-process samples","volume":"40","author":"R ten Have","year":"2012","journal-title":"Biologicals"},{"key":"ref23","first-page":"7","article-title":"Development of Inactivated Polio Vaccine (IPV) Derived from Attenuated Sabin Strains","author":"WAM Bakker","year":"2012","journal-title":"Proceedings of the 21st Annual Meeting of the European Society for Animal Cell Technology (ESACT), Dublin, Ireland, June"},{"key":"ref24","first-page":"31","article-title":"Fifthied report. Recommendations for the production and control of poliomyelitis vaccine (oral)","year":"2002","journal-title":"Technical Report Series No.904 World Health Organization."},{"key":"ref25","article-title":"Recommendations to assure the quality, safety and efficacy of live attenuated poliomyelitis vaccine (oral)","year":"2012","journal-title":"Replacement of TRS 904, annex 1 and addendum TRS 910, annex 1"},{"key":"ref26","first-page":"265","article-title":"Monolayer growth systems: homogeneous unit processes","year":"1985"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/bit.260110513","article-title":"Homogeneous cultivation of animal cells for the production of virus and virus products","volume":"11","author":"P van Hemert","year":"1969","journal-title":"Biotechnol Bioeng"},{"key":"ref28","first-page":"372","article-title":"Microcarrier cultures of animal cells. Tissue culture, methods and applications VII Cell propagations on culture supports","author":"AL van Wezel","year":"1973"},{"key":"ref29","first-page":"159","article-title":"New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines","volume":"41","author":"AL van Wezel","year":"1978","journal-title":"Dev Biol Stand"},{"key":"ref30","first-page":"187","article-title":"New trends in the preparation of cell substrates for the production of virus vaccines","volume":"5","author":"AL van Wezel","year":"1971","journal-title":"Prog Immunobiol Stand"},{"key":"ref31"},{"key":"ref32","first-page":"119","article-title":"Potency testing of killed polio vaccine in rats","volume":"47","author":"G van Steenis","year":"1981","journal-title":"Dev Biol Stand"},{"key":"ref33","article-title":"Note for guidance on preclinical pharmacological and toxicological testing of vaccines (CPMP\/SWP\/465\/95, June 1998).","year":"1998"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.vaccine.2012.12.076","article-title":"Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains","volume":"31","author":"J Westdijk","year":"2013","journal-title":"Vaccine"},{"key":"ref35","article-title":"Scale-down approach for animal-free polio vaccine production","year":"2010"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"J Westdijk","year":"2011","journal-title":"Vaccine"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1093\/clinids\/6.Supplement_2.S335","article-title":"Inactivated poliovirus vaccine: current production methods and new developments","volume":"6","author":"AL van Wezel","year":"1984","journal-title":"Rev Infect Dis"},{"key":"ref38","article-title":"Poliovirus vaccine-inactivated","year":"2013"},{"key":"ref39","first-page":"1","article-title":"Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 - conclusions and recommendations","volume":"88","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(12)61948-5","article-title":"Vaccination for whom? Time to reinvigorate Japanese vaccine policy","volume":"380","author":"T Tanimoto","year":"2012","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and Immunogenicity of Inactivated Poliovirus Vaccine Made From Sabin Strains: A Phase II, Randomized, Positive-Controlled Trial","volume":"205","author":"G Liao","year":"2012","journal-title":"J Infect Dis"},{"key":"ref42","article-title":"The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)","author":"G Liao","year":"2012"},{"key":"ref43","article-title":"Monograph 20616. Tests for extraneous agents in viral vaccines for human use.","year":"2011"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0083374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:05:38Z","timestamp":1588964738000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0083374"}},"subtitle":[],"editor":[{"given":"Paulo\u00a0Lee","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,12,12]]},"references-count":43,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2013,12,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0083374","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,12]]}}}